NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA,
HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR
RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY
OF THE SECURITIES DESCRIBED HEREIN.
Reference is made to the stock exchange announcement published by SoftOx
Solution AS (the "Company") 6th of July 2026, regarding the completion of the
Private Placement and the related Debt Conversion.
The following primary insider has been allocated new shares in the Private
Placement:
Ulrik Spork, Chairman of the Board of Directors of the Company, has subscribed
for 2,380,952 new shares. Following completion and registration of the share
issue, Ulrik Spork, together with wholly owned subsidiary Sporcon Lifescience
Advisors ApS, will hold 33,095,237 shares in the Company.
The notification of the transaction pursuant to Article 19 of the Market Abuse
Regulation is attached to this announcement.
on is attached to this announcement. \